For individuals with ITP ≥3 months who depend on corticosteroids or respond poorly to corticosteroids, the ASH guidelines suggest using second-line therapies, including TPO-RAs (once-daily oral eltrombopag or once-weekly subcutaneous injection romiplostim), rituximab, or splenectomy after appropriate immunizations (5). Here, TPO is linked to autoimmune thrombocytopenic purpura.